Lasofoxifene - Sermonix Pharmaceuticals

Drug Profile

Lasofoxifene - Sermonix Pharmaceuticals

Alternative Names: CP-336156; CP-336156-CB; Fablyn; Lasofoxifene tartrate; Oporia

Latest Information Update: 03 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ligand Pharmaceuticals; Pfizer
  • Developer Pfizer; Sermonix Pharmaceuticals
  • Class Antineoplastics; Osteoporosis therapies; Pyrrolidines; Small molecules; Tetrahydronaphthalenes
  • Mechanism of Action Estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Registered Postmenopausal osteoporosis
  • Preregistration Atrophic vaginitis
  • Phase III Breast cancer
  • Phase II Female sexual dysfunction
  • Research Ovarian cancer
  • No development reported Hypogonadism

Most Recent Events

  • 14 Nov 2017 Sermonix Pharmaceuticals plans a phase II trial for Breast cancer (Late-stage disease, Metastatic disease) in Europe and USA (PO) in the fourth quarter of 2018
  • 31 Oct 2017 Sermonix Pharmaceuticals files for patent protection for lasofoxifene for endocrine-resistant Breast cancer world-wide before October 2017
  • 03 Mar 2017 No development reported - Phase-I for Hypogonadism (In volunteers) in USA (PO) (Sermonix Pharmaceuticals pipeline, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top